API man­u­fac­tur­er Cam­brex buys Ha­lo Phar­ma for $425M — ven­tur­ing in­to fin­ished dose man­u­fac­tur­ing

In an­oth­er sign of con­sol­i­da­tion in the out­sourc­ing in­dus­try — fol­low­ing Catal­ent’s ac­qui­si­tion of Ju­niper just days ago — API man­u­fac­tur­er Cam­brex an­nounced its lat­est $425 mil­lion deal to snap up Ha­lo Phar­ma, which would add to both its prod­uct de­vel­op­ment and man­u­fac­tur­ing ca­pac­i­ties.

With a work­force of 450, Ha­lo Phar­ma runs two man­u­fac­tur­ing fa­cil­i­ties in Whip­pa­ny, NJ and Mon­tre­al that spe­cial­ize in “high­ly com­plex and dif­fi­cult to pro­duce for­mu­la­tions, prod­ucts for pe­di­atric in­di­ca­tions and con­trolled sub­stances.” East Ruther­ford, NJ-based Cam­brex al­so likes how Ha­lo’s ex­per­tise in oral solids, liq­uids and oint­ments will com­ple­ment its small mol­e­cule API busi­ness, which em­ploys 1,200 staffers be­tween US and Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER